Advertisement
The results of the 2009 Deloitte Technology Fast 50 China Program wereofficially released at an award presentation ceremony in Beijing. ChemPartnerwas the only company from the pharmaceutical and healthcare sector in the Top10 ranking.
Advertisement
"We are quite honored to be presented this award by Deloitte, which is aglobally acknowledged independent professional agency and consulting partner,"said Michael Hui, founder and CEO of Shanghai ChemPartner. "This is aremarkable recognition to our consistent efforts in strategically expandingand consolidating our R&D service portfolio, sharpening our core competencethrough improving internal operation efficiency."
"We will keep focusing more on our own development such as furtheroptimizing operational efficiency and attracting and retaining talent.Developing business in this uncertain economic environment has taught us theimportance of successful risk management; and we believe that improvingproductivity through careful strategic planning and innovation can helpcompanies achieve sustainable growth." Michael Hui added.
Mr. William Chou, Deloitte China's National Leader of Technology, Media &Telecommunications, said, "Backed by the country's strong economic expansionand government support for technological innovation, there is still much roomfor the Chinese hi-tech industry to grow. Significant overseas and domesticinvestments in innovative and growing Chinese companies are also drivingindustry development. It has been exciting to witness this vibrant growth anddevelopment through the Deloitte Technology Fast 50 China Program over thepast five years. The industry has continued to outperform, with manysuccessful players contributing to its dynamic development."
Mr. Chou continued, "We are glad to see that Chinese hi-tech companieshave invested a lot of effort into enhancing their competitiveness despiteexternal challenges. Looking forward, most hi-tech companies will continue ona recovery track from the financial crisis. We are pleased that many CEOs haveexpressed confidence in the future market and have said they will invest morein the research and development (R&D) of new products and technologies."
This is the fifth anniversary of the Deloitte Technology Fast 50 ChinaProgram since this global program was introduced in China in 2005. Thisprogram was designed to showcase the countries' emerging innovative companieswith great growth potential in the Telecom, Media, and Hi-Tech sectors. Itsannual Top lists have become an influential bellwether for global financialand investment circles. For the 2009 Deloitte Technology Fast 50 China Program,the Top 5 companies achieved an electrifying three-year average revenue growthranging from 1,771.02% to 29,576.86%. The Top 50 China Winning Companies willbe entered into the 2009 Deloitte Technology Fast 500 Asia & Pacific Program.
About Shanghai ChemPartner
Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one ofthe leading contract research organizations, providing medicinal chemistry,discovery biology, pharmacology, DMPK, toxicology, process R&D, analyticaldevelopment, formulation and contract manufacturing services to over 120pharmaceutical and biotech companies across the globe. ChemPartner currentlyhas a team of over 1000 scientists including nearly 100 senior scientificleaders with extensive industry experiences gained from leading globalpharmaceutical and biotech companies. Headquartered in China, ChemPartner hasoverseas business development operations at Boston, USA and Copenhagen,Denmark.
About ShangPharma
ShangPharma is a leading China-based outsourcing partner in pharmaceuticaland biotechnology research and development, who provides customized servicesto international pharmaceutical, biotech, agrochemical and chemical companies.As the holding company of Shanghai ChemPartner Co., Ltd. and ShanghaiChemExplorer Company Ltd., ShangPharma offers global pharmaceutical andbiotechnology companies comprehensive services and support for all of theirpreclinical R&D needs. ShangPharma currently has a team of more than 1,800professionals, and more than 60% of the employees have post graduateeducational experience of Master or Ph.D. degrees. ShangPharma has establishedcomprehensive R&D partnerships with world-class academic institutes,universities as well as healthcare industry and organizations, to contributemore added-value for its clients' success.
Further information is available at http://www.shangpharma.com .
SOURCE Shanghai ChemPartner Company Ltd.
